 |
Vol.43 No.7 contents | Japanese/English |
 | Full Text of PDF (63K) Article in Japanese |
- -
[title in Japanese]
Kazumasa Noda1Department of Thoracic Oncology, Kanagawa Cancer Center
Irinotecan hydrochloride is highly active in the treatment of small-cell lung cancer (SCLC) both in single use and combination with cisplatin. The arm of irinotecan plus cisplatin (IP) every 4 weeks for 4 cycles has significantly better survival for extensive-disease SCLC compared with the arm of etoposide and cisplatin (EP) every 3 weeks for 4 cycles, which was very representative and fine between previously reported results, without any difference of treatment compliance in either arm. Significantly more myelosuppression was observed in the IP arm, but on the contrary, significantly severe diarrhea was observed in the IP arm, especially in the initial courses of the regimen. In the arm, approximately one third of patients skipped the administration of irinotecan on day 8 and/or day 15, which was subsequently related to less dose intensity. Even though, irinotecan plus cisplatin every four weeks is considered to be a new standard treatment regimen against extensive-disease SCLC with good PS. Another phase III study has been conducted to reconfirm the result. It may also be posible for tailor-made therapy including irinotecan administration by meaning UGT1A1 polymorphism, to avoid severe toxicities.
key words: Irinotecan, Cisplatin, Etoposide, Small-cell lung cancer, UGT1A1 polymorphism
JJLC 43 (7): 844-849, 2003
